So far, many molecular markers have already been put into clinical use in the diagnosis of BC, and the main tumor markers comprise glycoantigen 153, glycoantigen 125, carcinoembryonic antigen, and HER2, the expression of which is crucial in the treatment of BC (8, 9). This evidence concerns the gene ERBB2 and breast cancer.